Long‐term outcome of living donor liver transplantation for primary biliary cirrhosis

@article{Kaneko2012LongtermOO,
  title={Long‐term outcome of living donor liver transplantation for primary biliary cirrhosis},
  author={Junichi Kaneko and Yasuhiko Sugawara and Sumihito Tamura and Taku Aoki and Kiyoshi Hasegawa and Noriyo Yamashiki and Norihiro Kokudo},
  journal={Transplant International},
  year={2012},
  volume={25}
}
In living donor liver transplantation (LDLT) for primary biliary cirrhosis (PBC), the majority of donors are genetically related to their recipients, leading to concerns of an earlier recurrence of PBC and a poorer prognosis due to genetic susceptibility. Totally 81 patients who underwent LDLT for PBC were the subjects of the present study. Immunosuppressive agents consisted of tacrolimus and methylprednisolone. In the outpatient clinic, when the aspartate and alanine aminotransferase level… 
Long‐Term Outcomes of Living‐Donor Liver Transplantation for Primary Biliary Cirrhosis: A Japanese Multicenter Study
  • H. Egawa, S. Sakisaka, +4 authors S. Uemoto
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2016
The factors that influence long‐term outcomes after living‐donor liver transplantation (LDLT) for primary biliary cirrhosis (PBC) are not well known. Compared with deceased‐donor transplantation,
[Liver transplantation for primary biliary cirrhosis].
  • T. Genda, T. Ichida
  • Medicine
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • 2013
TLDR
Liver transplantation remains the sole life-saving treatment method for PBC that has progressed to end-stage cirrhosis, and the results have been excellent compared with those for other diseases, with all studies reporting 5-year survival rates higher than 70 %.
Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study
TLDR
The timing of LT, recipient conditions, donor characteristics, and immunosuppressive medications may be associated with rPBC in LT recipients, a retrospective multicenter study in female patients after living‐donor LT.
Chronic immune-mediated reaction syndrome as the cause of late graft mortality in living-donor liver transplantation for primary biliary cirrhosis.
TLDR
Late graft mortality after LDLT for PBC in some patients was due to chronic immune-mediated reaction syndrome, including chronic rejection, veno-occlusive disease, and obliterative portal venopathy, but not to recurrent PBC.
Primary biliary cirrhosis and liver transplantation.
Primary biliary cirrhosis (PBC) is an immune-mediated chronic progressive inflammatory liver disease, predominantly affecting middle-aged women, characterized by the presence of antimitochondrial
Disease recurrence plays a minor role as a cause for retransplantation after living‐donor liver transplantation for primary biliary cirrhosis: A multicenter study in Japan
To clarify the role of disease recurrence as a cause of graft loss after living‐donor liver transplantation (LDLT) for primary biliary cirrhosis (PBC), we investigated explant grafts, as well as the
Liver Transplantation for Cholestatic Liver Diseases in Adults.
TLDR
Patient survival after LT for cholestatic liver diseases is generally better than for other indications and patients should be regularly assessed.
Longitudinal Assessment of Serum Creatinine Levels on Graft Survival After Renal Transplantation: Joint Modeling Approach
TLDR
The major finding of this study is that one unit increase in serum creatinine level suggests an increased risk of graft failure of up to four times.
Chapter 62 – Primary Biliary Cirrhosis
TLDR
Several informative transgene-based mouse models have been developed and confirm the nexus between AMA reactivity and cholangiocyte destruction, and experimental models are available supporting the participation in pathogenesis of environmental xenobiotics.
Post‐operative complications requiring hospitalization more than one yr after living donor liver transplantation
TLDR
The long‐term outcomes after living donor liver transplantation (LDLT) have not been clearly established and complications requiring hospitalization more than one yr after engraftment are reviewed.
...
1
2
...

References

SHOWING 1-10 OF 47 REFERENCES
The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation
  • J. Levitsky, J. Hart, S. Cohen, H. Te
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2003
TLDR
In this population of liver transplant recipients, recurrent PBC developed in a small number of patients 2 years or longer after OLT, and there was no difference in recurrence rates between those administered cyclosporine or tacrolimus for immunosuppression.
Primary biliary cirrhosis after liver transplantation: Influence of immunosuppression and human leukocyte antigen locus disparity
  • P. Manousou, V. Arvaniti, +7 authors A. Burroughs
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2010
TLDR
Azathioprine use in PBC patients who underwent transplantation was associated with less disease recurrence and a longer time to rPBC, and was not affected by HLA mismatches.
Long‐term follow‐up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients
TLDR
Multivariate analysis of the investigated patients showed that the recipient's age and Tac immunosuppression were significant risk factors for PBC recurrence, and long‐term follow‐up of up to 15 yr after liver transplantation, owing to PBC, in addition to maintenance of liver function, shows excellent organ and patient survival rates.
Recurrent Primary Biliary Cirrhosis After Liver Transplantation
TLDR
While short‐ and medium‐term outcomes remain favorable, especially if compared to patients transplanted for other indications, continued follow-up may identify reduced long‐term graft and patient survival.
Long‐term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation
  • P. Charatcharoenwitthaya, S. Pimentel, +4 authors R. Wiesner
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2007
TLDR
While UDCA therapy is associated with biochemical improvement, its role in delaying histologic progression remains unknown and in this short period of treatment, UDCA was not associated with improved patient and graft survival compared to untreated patients.
Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis
  • D. Morioka, H. Egawa, +7 authors Koichi Tanaka
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2007
TLDR
The absence of persistent ascites before LDLT, a lower number of HLA‐A, ‐B, and ‐DR mismatches between donor and recipient, and a younger donor (<50 years) are preferred for gaining acceptable survival outcomes for the transplant, however, a higher number of SOTA mismatches or the average trough level of tacrolimus within 1 year after LDLT may be a risk factor for PBC recurrence.
Liver transplantation for primary biliary cirrhosis: A long‐term pathologic study
  • U. Khettry, N. Anand, +5 authors F. Gordon
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2003
TLDR
Recurrence of autoimmune liver disease was seen in 30% of patients after LT for PBC and had features of P BC and/or AILD‐NOS; patients with no recurrent disease had shorter follow‐up periods and more frequent immunosuppression, including AZA; some may still develop recurrence with longer follow-up.
Cyclosporine A Protects Against Primary Biliary Cirrhosis Recurrence After Liver Transplantation
TLDR
Although PBC transplant recipients receiving CsA have a lower risk of disease recurrence, the development of recurrent PBC did not impact on long‐term patient survival.
Optimal timing of liver transplantation for primary biliary cirrhosis
TLDR
The data suggest that an optimal timing for liver transplantation, as determined by patient survival and resource utilization, appears to be at a risk score around 7.8 in patients with PBC.
Recurrent primary biliary cirrhosis: Peritransplant factors and ursodeoxycholic acid treatment post‐liver transplant
  • J. Guy, P. Qian, J. Lowell, M. Peters
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2005
TLDR
It is concluded that recurrent PBC is not infrequent post‐OLT, and ursodeoxycholic acid can be used with some benefit post‐ OLT, while treatment effects on long‐term survival are not known.
...
1
2
3
4
5
...